Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 71

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 71
---
The exercise price of the March 2024 Common Warrants, and the number of March 2024 Common Warrant Shares, is subject to adjustment in the event of any stock dividend or split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the March 2024 Common Warrants.

A holder does not have the right to exercise any portion of the March 2024 Common Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, upon election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of such warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.

| 38 |

In the event of a Fundamental Transaction (as such term is defined in the March 2024 Common Warrant), then the successor entity will succeed to, and be substituted for the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations under the March 2024 Common Warrants with the same effect as if such successor entity had been named in the warrant itself. If holders of Common Stock are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder shall be given the same choice as to the consideration it receives upon any exercise of the March 2024 Common Warrants following such Fundamental Transaction. In addition, the successor entity, at the request of holders of the March 2024 Common Warrants, will be obligated to purchase any unexercised portion of the March 2024 Common Warrants in accordance with the terms thereof. Notwithstanding the foregoing, in the event of a Fundamental Transaction, the holders of the March 2024 Common Warrants have the right to require the Company or a successor entity to redeem the March 2024 Common Warrants for cash in the amount of the Black Scholes Value (as defined in the March 2024 Common Warrant) of the unexercised portion of the March 2024 Common Warrants concurrently with or within 30 days following the consummation of a Fundamental Transaction. However, in the event of a fundamental transaction which is not in our control, including a Fundamental Transaction not approved by the Company’s board of directors, the holders of the